Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

RINVOQ 30 mg prolonged-release tablets

Active Ingredient:
upadacitinib hemihydrate
Company:  
AbbVie Ltd See contact details
ATC code: 
L04AF03
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials Letters to HCPs HCP Med Info
{arrow_left}
{arrow_right}

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

{pdf_link}

RINVOQ HCP Guide

{healthcare_pro_orange} For Healthcare Professionals
Rinvoq Healthcare Professional Educational Guide
{pdf_link}

RINVOQ Patient Card (Great Britain)

RINVOQ Patient Card - for medicines containing Upadacitinib

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

AbbVie Ltd
Company image
Address
AbbVie House, Vanwall Business Park, Vanwall Road, Maidenhead, Berkshire, SL6 4UB, UK
Telephone
+44 (0)1628 561 092
Medical Information e-mail
[email protected]
Out of Hours Telephone
+44 (0)1628 561 092
WWW
www.abbviemedinfo.com
WWW
www.abbvie.co.uk